- Home
- STKS vs SGMT Comparison
STKS vs SGMT Comparison
Compare STKS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STKS
- SGMT
- Stock Information
- Founded
- STKS 2004
- SGMT 2006
- Country
- STKS United States
- SGMT United States
- Employees
- STKS N/A
- SGMT N/A
- Industry
- STKS Restaurants
- SGMT
- Sector
- STKS Consumer Discretionary
- SGMT
- Exchange
- STKS Nasdaq
- SGMT Nasdaq
- Market Cap
- STKS 104.0M
- SGMT 93.7M
- IPO Year
- STKS N/A
- SGMT 2023
- Fundamental
- Price
- STKS $3.02
- SGMT $4.73
- Analyst Decision
- STKS Buy
- SGMT Strong Buy
- Analyst Count
- STKS 3
- SGMT 5
- Target Price
- STKS $6.83
- SGMT $21.60
- AVG Volume (30 Days)
- STKS 122.7K
- SGMT 792.4K
- Earning Date
- STKS 11-07-2024
- SGMT 11-13-2024
- Dividend Yield
- STKS N/A
- SGMT N/A
- EPS Growth
- STKS N/A
- SGMT N/A
- EPS
- STKS N/A
- SGMT N/A
- Revenue
- STKS $541,400,000.00
- SGMT N/A
- Revenue This Year
- STKS $118.51
- SGMT N/A
- Revenue Next Year
- STKS $34.44
- SGMT N/A
- P/E Ratio
- STKS N/A
- SGMT N/A
- Revenue Growth
- STKS 63.49
- SGMT N/A
- 52 Week Low
- STKS $2.92
- SGMT $2.31
- 52 Week High
- STKS $6.45
- SGMT $20.71
- Technical
- Relative Strength Index (RSI)
- STKS 37.77
- SGMT 41.81
- Support Level
- STKS $3.06
- SGMT $5.61
- Resistance Level
- STKS $3.19
- SGMT $6.40
- Average True Range (ATR)
- STKS 0.18
- SGMT 0.53
- MACD
- STKS -0.05
- SGMT -0.16
- Stochastic Oscillator
- STKS 9.90
- SGMT 8.24
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Kona Grill, ONE Hospitality, and Corporate. The company generates the vast majority of its revenue from the domestic market.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).